Single-cell genomics is becoming the cornerstone of drug development, clinical diagnosis and basic scientific research.
It is reported that “Baiao Zhihui” has recently completed A+ round of financing. This round of financing was led by SoftBank China Capital, and IDG Capital and Xingze Capital participated in the investment. This is another round of financing after the company’s IDG Capital A round of investment in 2019.
The funds raised will be used to further expand and accelerate the transformation and application of single-cell big data and single-cell data analysis platform in the field of innovative drug research and development, and promote its single-cell big data and analysis system in new drug development. Target mining, biological immunological verification, antibody development, biomarker discovery, basic scientific research and clinical research have established market advantages; at the same time, it will further expand the commercialization layout at home and abroad.
“Baiao Zhihui” was established at the end of 2018 and is engaged in applying single-cell omics and bioinformatics to the diagnosis and treatment of human diseases, by creating Accurate cell atlas, looking for new breakthrough treatment and diagnosis methods.
Specifically,“Baoao Zhihui” currently focuses on In the research and development of drug targets and biomarkers, single-cell big data commercial analysis platform and single-cell big data integrated management system; and set up dual operation centers in China and the United States , While expanding domestic and international markets.
Professor Zhang Zemin, the founder of “BIOPIC” and Peking University Biomedical Frontier Innovation Center (BIOPIC), said that single-cell genomics is becoming a drug development and clinical diagnosis And the cornerstone of basic scientific research.
